(Q34608306)

3 August 2017

title

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD (English)

1 reference

3 August 2017

1 reference

1 reference

1 reference

11

Mauricio Maia

1 reference

3 August 2017

Robert L Avery

1

1 reference

3 August 2017

Alessandro A Castellarin

2

1 reference

3 August 2017

Nathan C Steinle

3

1 reference

3 August 2017

Dilsher S Dhoot

4

1 reference

3 August 2017

Dante Joseph Pieramici

5

1 reference

3 August 2017

Robert See

6

1 reference

3 August 2017

Stephen Couvillion

7

1 reference

3 August 2017

Ma'an A Nasir

8

1 reference

3 August 2017

Melvin D Rabena

9

1 reference

3 August 2017

Kha Le

10

1 reference

3 August 2017

Jennifer E Visich

12

1 reference

3 August 2017

language of work or name

English

0 references

publication date

7 July 2014

1 reference

3 August 2017

number of pages

6

1 reference

British Journal of Ophthalmology

inferred from page(s)

published in

1 reference

3 August 2017

volume

98

1 reference

3 August 2017

issue

12

1 reference

3 August 2017

page(s)

1636-1641

1 reference

What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

Aflibercept (VEGF-TRAP): the next anti-VEGF drug

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

Adverse effects of anticancer agents that target the VEGF pathway

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

Anti-macular degeneration agents

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

VEGF-Trap: a VEGF blocker with potent antitumor effects

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4251300

Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach

7 July 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305252

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305252

Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305252

Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305252

Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305252

Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305252

Comparing protein VEGF inhibitors: In vitro biological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305252

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305252

Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25001321

12 December 2020

inferred from PubMed ID database lookup

Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25001321

12 December 2020

inferred from PubMed ID database lookup

Cerebrovascular accidents in patients treated for choroidal neovascularization with ranibizumab in randomized controlled trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25001321

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1136/BJOPHTHALMOL-2014-305252

1 reference

3 August 2017

1 reference

3 August 2017

1 reference